Eagle Pharmaceuticals, Inc. (EGRX): Price and Financial Metrics


Eagle Pharmaceuticals, Inc. (EGRX): $40.40

-4.98 (-10.97%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EGRX Stock Summary

  • EGRX's current price/earnings ratio is 119.77, which is higher than 91.63% of US stocks with positive earnings.
  • For EGRX, its debt to operating expenses ratio is greater than that reported by only 22.29% of US equities we're observing.
  • The volatility of Eagle Pharmaceuticals Inc's share price is greater than that of merely 11.18% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Eagle Pharmaceuticals Inc are NEWR, SVMK, HCAT, RAMP, and NTNX.
  • EGRX's SEC filings can be seen here. And to visit Eagle Pharmaceuticals Inc's official web site, go to www.eagleus.com.

EGRX Stock Price Chart Interactive Chart >

Price chart for EGRX

EGRX Price/Volume Stats

Current price $40.40 52-week high $56.16
Prev. close $45.38 52-week low $33.80
Day low $40.40 Volume 185,525
Day high $44.54 Avg. volume 120,186
50-day MA $47.75 Dividend yield N/A
200-day MA $46.46 Market Cap 526.41M

Eagle Pharmaceuticals, Inc. (EGRX) Company Bio


Eagle Pharmaceuticals focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company was founded in 2007 and is based in Woodcliff Lake, New Jersey.

EGRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$40.40$48.96 8%

Below please find a table outlining a discounted cash flow forecast for EGRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Eagle Pharmaceuticals Inc ranked in the 55th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Eagle Pharmaceuticals Inc ended up being:

  • The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than merely 18.48% of the free cash flow producing stocks we're observing.
  • As a business, Eagle Pharmaceuticals Inc experienced a tax rate of about 36% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 92.53% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%6%
1%7%
2%8%
3%9%
4%10%
5%11%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as EGRX, try PTPI, HOLX, CMD, GSK, and PBH.


EGRX Latest News Stream


Event/Time News Detail
Loading, please wait...

EGRX Latest Social Stream


Loading social stream, please wait...

View Full EGRX Social Stream

Latest EGRX News From Around the Web

Below are the latest news stories about Eagle Pharmaceuticals Inc that investors may wish to consider to help them evaluate EGRX as an investment opportunity.

Earnings Preview: Eagle Pharmaceuticals

Eagle Pharmaceuticals (NASDAQ:EGRX) announces its next round of earnings this Tuesday, March 02. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement. What Are Earnings, Net Income, And Earnings Per Share? Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS. Earnings And Revenue Sell-side analysts are expecting Eagle Pharmaceuticals's loss per share to be near $0.17 on sales of $53.16 million. In the same quarter last year, Eagle Pharmaceuticals announced EPS of $0.48 on revenue of $48.26 million. Why Analyst Estimates And Earnings Surprises Are Important Wall Street analysts who study t...

Yahoo | March 1, 2021

Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin. Eagle has now had two conversations with FDA regarding the CRL and will have an additional meeting with FDA within 30 days. Importantly, Eagle has completed an extensive amount of developmental work and continu

Business Wire | February 2, 2021

Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 29, 2021, the United States District Court for the District of Delaware (the “Court”) postponed the February 1, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. The Court expects to hold a call with the parties today to discuss a new trial date. Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals, stated, “Par’

Business Wire | February 1, 2021

SEEDS - Access Changes Everything Announces Multi-Year Partnership with Eagle Pharmaceuticals

NEWARK, N.J., Jan. 28, 2021 /PRNewswire/ -- SEEDS – Access Changes Everything (SEEDS) is pleased to announce a new, multi-year partnership with Eagle Pharmaceuticals that will provide educational funding for 12 high-achieving students over the course of two years, while also supporting…

PR Newswire | January 28, 2021

Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern. The trial is now scheduled to begin remotely starting February 1, 2021 and is exp

Business Wire | January 11, 2021

Read More 'EGRX' Stories Here

EGRX Price Returns

1-mo -13.43%
3-mo -13.42%
6-mo 6.15%
1-year -3.49%
3-year -24.67%
5-year -38.14%
YTD -13.25%
2020 -22.49%
2019 49.12%
2018 -24.58%
2017 -32.67%
2016 -10.52%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8364 seconds.